Bristol-Myers Squibb Compnay

Khehyong Ngu

Saleem Ahmad

Jeffrey A Robl

William N Washburn

David S Weinstein

John E Macor

Scott Hunter Watterson

Qingjie Liu

Karnail S Atwal

Shung C Wu

Philip D Stein

Jun Li

T G Murali Dhar

John V Duncia

Douglas G Batt

Steven V O'Neil

Sharon N Bisaha

William John Pitts

Jingwu Duan

Joseph B Santella

Joseph Anthony Tino

Robert J Cherney

Daniel S Gardner

Hai-Yun Xiao

Upender Velaparthi

Bin Jiang

Zhonghui Lu

Lawrence J Kennedy

Andrew J Tebben

Andres S Hernandez

Zheming Ruan

Hua Gong

Anurag S Srivastava

Steven J Walker

Hasibur Rahaman

Weiwei Guo

Haixia Wang

Lan-Ying Qin

Myra Beaudoin Bertrand

Zhenghua Wang

Ning Li

Christopher Annunziato

Wayne David Vaccaro

Robert Joseph Cherney

Brian Edward Fink

Pravin S Shirude

The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, (I) wherein ring A, A, A, A, A, Q, R, R, R, R, R, and Ralong with other variables are as defined herein.

Macrocyclic PAD4 inhibitors useful as immunosuppressant

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; R, R, R, R, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Indole carboxamide compounds

The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein. 

Indole and azaindole inhibitors of pad enzymes

Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CRor N; B is CRor N; D is CRor N; Lis &#x2014;(CRR)&#x2014;; Lis &#x2014;(CRR)&#x2014;; and X, Z, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Heterocyclic compounds useful as modulators of TNF alpha

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds. 

Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators

MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R, R, R, R, and Rare defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I. 

Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists

The present invention provides pyrazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.

Pyrazolyl inhibitors of 15-lipoxygenase

Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis wherein X is N or CR;and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined herein. A method for treating the above diseases employing the above compounds is also provided.

HMG-CoA reductase inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C&#x2014;Rwherein Ris H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group, R, R, Rand Rare as defined herein, and where X is N, Ris preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Heterocyclic sodium/proton exchange inhibitors and method

The present invention provides imidazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.

Imidazolyl inhibitors of 15-lipoxygenase

Growing community of inventors

Pennington, NJ, United States of America

Khehyong Ngu